Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing Weekly

Review of hedge fund launches, closures, trends, regulatory and legal events - week 34

Saturday, August 28, 2010

Benedicte Gravrand, Opalesque London:

Last week, we heard of fund launches from new firm AlphaNex Capital (systematic hedge fund); Universal-Investment and York A.M. (global merger arbitrage absolute return Ucits fund); Bridgewater (more liquid version of hedge fund); Ayaltis (distressed credit FoHFs); Key A.M. (Newcits); and eStats (high frequency futures trading).

Paolo Pellegrini, CEO of New York-based PSQR Capital, announced he would close down and redeem money to investors on September 30 after his fund fell 11% this year, despite gaining more than 60% in 2009.

The Morningstar 1000 Hedge Fund Index rose +2.7% in July (0.4%YTD), as funds saw outflows of $1.6bn in the first half of year.

Not much news this week, but a lot of digging in the past instead: Jon Wood, founder of the SRM Global hedge fund was revealed to have been the second most generous Tory donor during the recent UK election; listed fund Brevan Howard reported revenues of more than $1bn for the first time and it was made known that partners at the firm had shared a GBP86m bonus during the financial crisis; and at last, Forbes reported that Yorkville Advisors had handed over key documents to SEC in 2009 to aid a probe.

The Merrion High Alpha hedge fund opened to outside investors; Moody Aldrich Partners and Wilshire Associates teamed up to launch a hedge fund seeding platform; fund manager Jupiter was in the black in H1 with GBP14.6m profit, but suffered outflows from hedge funds; Hedgebay reported that illiquid trading had dominated as the secondary market awaited the retu......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for